Page last updated: 2024-12-04

4-amino-3-hydroxybutyric acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4-amino-3-hydroxybutyric acid: RN given refers to cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

gamma-amino-beta-hydroxybutyric acid : A gamma-amino acid comprising 4-aminobutyric acid having a 2-hydroxy substituent. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID2149
CHEMBL ID93515
CHEBI ID16080
SCHEMBL ID38621
MeSH IDM0045557

Synonyms (128)

Synonym
CHEMBL93515
CHEBI:16080 ,
bogil
gamibetal
.beta.-hydroxy-.gamma.-aminobutyrate
.gamma.-amino-.beta.-hydroxybutyrate
idramina
3-hydroxy-4-aminobutyric acid
butanoic acid, 4-amino-3-hydroxy-
4-amino-3-hydroxybutyric acid
buksamin
gabobe
.gamma.-amino-.beta.-hydroxybutyric acid
gabimex
gabomade
3-hydroxy-gaba
gaminal
gaboril
buxamine
.beta.-hydroxy-.gamma.-aminobutyric acid
butyric acid, 4-amino-3-hydroxy-
nsc-40244
nsc40244
KBIO1_000116
DIVK1C_000116
buxamin
buxamine (van)
gamma-amino-beta-hydroxybutyrate
einecs 213-106-9
d,l-4-amino-3-hydroxybutyric acid
einecs 206-518-5
(+-)-4-amino-3-hydroxybutyric acid
beta-oxy-gaba
dl-4-amino-3-hydroxybutyric acid
nsc 40244
beta-hydroxy-gamma-aminobutyrate
gamma-amino-beta-hydroxybutyric acid [jan]
beta-hydroxy-alpha-aminobutyric acid
gamma-amino-beta-hydroxybutyric acid (jan)
D00174
SPECTRUM_001276
SPECTRUM5_001124
BSPBIO_002996
IDI1_000116
C03678
4-amino-3-hydroxybutanoic acid
352-21-6
gamma-amino-beta-hydroxybutyric acid
gabob
4-amino-3-hydroxybutyric acid, 98%
NCGC00094987-02
NCGC00094987-01
KBIO3_002496
KBIOGR_000882
KBIOSS_001756
KBIO2_001756
KBIO2_004324
KBIO2_006892
SPECTRUM3_001548
SPECTRUM4_000301
NINDS_000116
SPECTRUM2_001129
SPBIO_000997
SPECTRUM1503041
NCGC00094987-03
80297B30-DF98-4F62-A800-277359B3BBE8
924-49-2
A0318
yqgdepyyfwupgo-uhfffaoysa-
inchi=1/c4h9no3/c5-2-3(6)1-4(7)8/h3,6h,1-2,5h2,(h,7,8)
4-amino-3-hydroxy-butanoic acid
HMS500F18
HMS1922A11
4-amino-3-hydroxy-butyric acid
A844239
3-hydroxy-4-amino-butyric acid
1zhm019fld ,
unii-1zhm019fld
nsc-758215
nsc758215
pharmakon1600-01503041
cas-924-49-2
dtxcid9025877
dtxsid1045877 ,
tox21_111375
CCG-40012
FT-0632015
FT-0636333
FT-0636332
AKOS015892786
AB3028
(+/-)-4-amino-3-hydroxybutyric acid
4-amino-3-hydroxybutyric acid [mi]
4-amino-3-hydroxybutyric acid [inci]
4-amino-3-hydroxybutyric acid [who-dd]
butanoic acid, 4-amino-3-hydroxy-, (+/-)-
4-amino-3-hydroxybutyric acid [mart.]
butyric acid, 4-amino-3-hydroxy-, dl-
rac-4-amino-3-hydroxybutyric acid
3-hydroxy-4-amino butanoic acid
gamma-amino-3-hydroxybutyric acid
SCHEMBL38621
(s)-4-amino-3-hydroxybutyric acid
butanoic acid, 4-amino-3-hydroxy-, (.+/-.)-
.gamma.-amino-.beta.-hydroxy-n-butyric acid
.beta.-hydroxy-gaba
(.+/-.)-4-amino-3-hydroxybutyric acid
4-amino-3-hydroxybutanoic acid #
AB00052302_02
mfcd00008141
SR-01000872771-1
sr-01000872771
SBI-0051753.P002
4-amino-3-hydroxybutyrate
FT-0716832
Q5520257
AS-44677
dl-4-amino-3-hydroxybutanoic acid
4-amino-3-hydroxybutanoicacid
(s)-4-amino-3-hydroxybutyricacid
HY-B1427
CS-0013138
3-hydroxy-4-amino butyric acid
EN300-96299
SY045503
SY050892
SY110230
Z1255390571

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" The results show that the compound is well absorbed and retained by the organism."( Absorption, distribution and excretion of DL-gamma-amino-beta-hydroxybutyric acid-1-14C (GABOB-1-14C) in the rat.
Bonardi, G; Mondino, A; Silvestri, S; Zanolo, G, 1981
)
0.26
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (3)

ClassDescription
amino acid zwitterionThe zwitterionic form of an amino acid having a negatively charged carboxyl group and a positively charged amino group.
gamma-amino acidA non-proteinogenic amino-acid in which the amino group is located on the carbon atom at the position gamma to the carboxy group.
3-hydroxy monocarboxylic acidA hydroxy monocarboxylic acid that has a hydroxy group beta to the carboxy group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (3)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
estrogen nuclear receptor alphaHomo sapiens (human)Potency16.78550.000229.305416,493.5996AID743079
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency14.12540.01789.637444.6684AID588834
lamin isoform A-delta10Homo sapiens (human)Potency35.48130.891312.067628.1838AID1487
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (11)

Assay IDTitleYearJournalArticle
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID227699Virtual screen for compounds with anticonvulsant activity2003Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16
Topological virtual screening: a way to find new anticonvulsant drugs from chemical diversity.
AID49192Affinity of compound towards the carnitine/acylcarnitine translocase was determined by monitoring the efflux of [14C]L-carnitine from isolated rat heart mitochondria1986Journal of medicinal chemistry, May, Volume: 29, Issue:5
Synthesis and biological evaluation of cyclic analogues of 1-carnitine as potential agents in the treatment of myocardial ischemia.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (70)

TimeframeStudies, This Drug (%)All Drugs %
pre-199052 (74.29)18.7374
1990's3 (4.29)18.2507
2000's5 (7.14)29.6817
2010's9 (12.86)24.3611
2020's1 (1.43)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 20.85

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index20.85 (24.57)
Research Supply Index4.33 (2.92)
Research Growth Index4.59 (4.65)
Search Engine Demand Index21.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (20.85)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (1.35%)5.53%
Reviews3 (4.05%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other70 (94.59%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]